Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating) has earned an average rating of “Buy” from the fourteen research firms that are covering the company, Marketbeat reports. Thirteen equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year is $54.58.

A number of equities analysts recently commented on the company. Wedbush dropped their price target on Denali Therapeutics from $46.00 to $38.00 and set an “outperform” rating for the company in a research note on Tuesday, February 28th. HC Wainwright reissued a “buy” rating and set a $105.00 price target on shares of Denali Therapeutics in a research note on Thursday, February 23rd. Morgan Stanley increased their price target on Denali Therapeutics from $61.00 to $63.00 and gave the company an “overweight” rating in a research note on Wednesday, April 12th. Stifel Nicolaus dropped their price target on Denali Therapeutics to $30.00 in a research note on Tuesday, May 9th. Finally, SVB Leerink reissued an “outperform” rating and set a $50.00 price target on shares of Denali Therapeutics in a research note on Monday, January 30th.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 5,102 shares of the firm’s stock in a transaction on Wednesday, April 12th. The stock was sold at an average price of $25.04, for a total value of $127,754.08. Following the completion of the sale, the insider now owns 528,691 shares of the company’s stock, valued at approximately $13,238,422.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Denali Therapeutics news, insider Alexander O. Schuth sold 10,000 shares of Denali Therapeutics stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $28.60, for a total transaction of $286,000.00. Following the completion of the sale, the insider now owns 528,691 shares of the company’s stock, valued at approximately $15,120,562.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander O. Schuth sold 5,102 shares of Denali Therapeutics stock in a transaction dated Wednesday, April 12th. The stock was sold at an average price of $25.04, for a total value of $127,754.08. Following the sale, the insider now directly owns 528,691 shares of the company’s stock, valued at approximately $13,238,422.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,302 shares of company stock valued at $418,754. 12.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

A number of institutional investors have recently modified their holdings of DNLI. China Universal Asset Management Co. Ltd. raised its stake in shares of Denali Therapeutics by 34.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 1,851 shares of the company’s stock valued at $43,000 after buying an additional 471 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Denali Therapeutics by 85.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,669 shares of the company’s stock valued at $46,000 after buying an additional 768 shares during the last quarter. Sandia Investment Management LP purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at about $70,000. Exchange Traded Concepts LLC increased its stake in shares of Denali Therapeutics by 18.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 2,584 shares of the company’s stock valued at $72,000 after purchasing an additional 408 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Denali Therapeutics by 157.7% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,005 shares of the company’s stock valued at $92,000 after purchasing an additional 2,451 shares in the last quarter. Hedge funds and other institutional investors own 67.26% of the company’s stock.

Denali Therapeutics Stock Up 4.1 %

NASDAQ DNLI opened at $31.58 on Friday. The firm has a market cap of $4.32 billion, a price-to-earnings ratio of -11.00 and a beta of 1.33. The business has a 50-day moving average price of $25.11 and a 200-day moving average price of $27.76. Denali Therapeutics has a twelve month low of $20.76 and a twelve month high of $39.43.

Denali Therapeutics (NASDAQ:DNLI – Get Rating) last released its quarterly earnings data on Monday, May 8th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.10). The business had revenue of $35.14 million during the quarter, compared to the consensus estimate of $29.88 million. Denali Therapeutics had a negative return on equity of 40.01% and a negative net margin of 365.21%. The business’s revenue was down 16.6% on a year-over-year basis. During the same period last year, the company earned ($0.53) EPS. Research analysts expect that Denali Therapeutics will post -3.31 EPS for the current fiscal year.

Denali Therapeutics Company Profile

(Get Rating)

Denali Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.